Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Genetic test utilization and diagnostic yield in adult patients with neurological disorders.

Bardakjian TM, Helbig I, Quinn C, Elman LB, McCluskey LF, Scherer SS, Gonzalez-Alegre P.

Neurogenetics. 2018 May;19(2):105-110. doi: 10.1007/s10048-018-0544-x. Epub 2018 Mar 28.

PMID:
29589152
2.

Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases.

Sheinerman KS, Toledo JB, Tsivinsky VG, Irwin D, Grossman M, Weintraub D, Hurtig HI, Chen-Plotkin A, Wolk DA, McCluskey LF, Elman LB, Trojanowski JQ, Umansky SR.

Alzheimers Res Ther. 2017 Nov 9;9(1):89. doi: 10.1186/s13195-017-0316-0.

3.

Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis.

Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, Prudencio M, Carlomagno Y, Daughrity LM, Jansen-West K, Perkerson EA, O'Raw A, Cook C, Pregent L, Belzil V, van Blitterswijk M, Tabassian LJ, Lee CW, Yue M, Tong J, Song Y, Castanedes-Casey M, Rousseau L, Phillips V, Dickson DW, Rademakers R, Fryer JD, Rush BK, Pedraza O, Caputo AM, Desaro P, Palmucci C, Robertson A, Heckman MG, Diehl NN, Wiggs E, Tierney M, Braun L, Farren J, Lacomis D, Ladha S, Fournier CN, McCluskey LF, Elman LB, Toledo JB, McBride JD, Tiloca C, Morelli C, Poletti B, Solca F, Prelle A, Wuu J, Jockel-Balsarotti J, Rigo F, Ambrose C, Datta A, Yang W, Raitcheva D, Antognetti G, McCampbell A, Van Swieten JC, Miller BL, Boxer AL, Brown RH, Bowser R, Miller TM, Trojanowski JQ, Grossman M, Berry JD, Hu WT, Ratti A, Traynor BJ, Disney MD, Benatar M, Silani V, Glass JD, Floeter MK, Rothstein JD, Boylan KB, Petrucelli L.

Sci Transl Med. 2017 Mar 29;9(383). pii: eaai7866. doi: 10.1126/scitranslmed.aai7866.

4.

Defining SOD1 ALS natural history to guide therapeutic clinical trial design.

Bali T, Self W, Liu J, Siddique T, Wang LH, Bird TD, Ratti E, Atassi N, Boylan KB, Glass JD, Maragakis NJ, Caress JB, McCluskey LF, Appel SH, Wymer JP, Gibson S, Zinman L, Mozaffar T, Callaghan B, McVey AL, Jockel-Balsarotti J, Allred P, Fisher ER, Lopate G, Pestronk A, Cudkowicz ME, Miller TM.

J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):99-105. doi: 10.1136/jnnp-2016-313521. Epub 2016 Jun 3.

5.

Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration.

Suh E, Lee EB, Neal D, Wood EM, Toledo JB, Rennert L, Irwin DJ, McMillan CT, Krock B, Elman LB, McCluskey LF, Grossman M, Xie SX, Trojanowski JQ, Van Deerlin VM.

Acta Neuropathol. 2015 Sep;130(3):363-72. doi: 10.1007/s00401-015-1445-9. Epub 2015 May 29.

6.

Atypical Alzheimer's disease in an elderly United States resident with amyotrophic lateral sclerosis and pathological tau in spinal motor neurons.

McCluskey LF, Geser F, Elman LB, Van Deerlin VM, Robinson JL, Lee VM, Trojanowski JQ.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):466-72. doi: 10.3109/21678421.2014.903973. Epub 2014 May 9. No abstract available.

7.

Topography of FUS pathology distinguishes late-onset BIBD from aFTLD-U.

Lee EB, Russ J, Jung H, Elman LB, Chahine LM, Kremens D, Miller BL, Branch Coslett H, Trojanowski JQ, Van Deerlin VM, McCluskey LF.

Acta Neuropathol Commun. 2013 May 9;1(9):1-11.

8.

Whole-brain analysis of amyotrophic lateral sclerosis by using echo-planar spectroscopic imaging.

Verma G, Woo JH, Chawla S, Wang S, Sheriff S, Elman LB, McCluskey LF, Grossman M, Melhem ER, Maudsley AA, Poptani H.

Radiology. 2013 Jun;267(3):851-7. doi: 10.1148/radiol.13121148. Epub 2013 Jan 29.

9.

Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis.

Irwin DJ, McMillan CT, Brettschneider J, Libon DJ, Powers J, Rascovsky K, Toledo JB, Boller A, Bekisz J, Chandrasekaran K, Wood EM, Shaw LM, Woo JH, Cook PA, Wolk DA, Arnold SE, Van Deerlin VM, McCluskey LF, Elman L, Lee VM, Trojanowski JQ, Grossman M.

J Neurol Neurosurg Psychiatry. 2013 Feb;84(2):163-9. doi: 10.1136/jnnp-2012-303507. Epub 2012 Oct 31.

10.

Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design.

Miller RG, Moore DH, Forshew DA, Katz JS, Barohn RJ, Valan M, Bromberg MB, Goslin KL, Graves MC, McCluskey LF, McVey AL, Mozaffar T, Florence JM, Pestronk A, Ross M, Simpson EP, Appel SH; WALS Study Group.

Neurology. 2011 Sep 6;77(10):973-9. doi: 10.1212/WNL.0b013e31822dc7a5. Epub 2011 Aug 3.

11.

Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy.

Geser F, Stein B, Partain M, Elman LB, McCluskey LF, Xie SX, Van Deerlin VM, Kwong LK, Lee VM, Trojanowski JQ.

Acta Neuropathol. 2011 Apr;121(4):509-17. doi: 10.1007/s00401-011-0797-z. Epub 2011 Jan 12.

12.

Quantitative proton magnetic resonance spectroscopy detects abnormalities in dorsolateral prefrontal cortex and motor cortex of patients with frontotemporal lobar degeneration.

Chawla S, Wang S, Moore P, Woo JH, Elman L, McCluskey LF, Melhem ER, Grossman M, Poptani H.

J Neurol. 2010 Jan;257(1):114-21. doi: 10.1007/s00415-009-5283-3. Epub 2009 Aug 18.

13.

Amyotrophic lateral sclerosis-plus syndrome with TAR DNA-binding protein-43 pathology.

McCluskey LF, Elman LB, Martinez-Lage M, Van Deerlin V, Yuan W, Clay D, Siderowf A, Trojanowski JQ.

Arch Neurol. 2009 Jan;66(1):121-4. doi: 10.1001/archneur.66.1.121.

14.

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.

Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, Barkhaus PE, Bosch P, Boylan K, David WS, Feldman E, Glass J, Gutmann L, Katz J, King W, Luciano CA, McCluskey LF, Nash S, Newman DS, Pascuzzi RM, Pioro E, Sams LJ, Scelsa S, Simpson EP, Subramony SH, Tiryaki E, Thornton CA.

Neurology. 2008 Nov 25;71(22):1770-5. doi: 10.1212/01.wnl.0000335970.78664.36.

15.

A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.

Gordon PH, Cheung YK, Levin B, Andrews H, Doorish C, Macarthur RB, Montes J, Bednarz K, Florence J, Rowin J, Boylan K, Mozaffar T, Tandan R, Mitsumoto H, Kelvin EA, Chapin J, Bedlack R, Rivner M, McCluskey LF, Pestronk A, Graves M, Sorenson EJ, Barohn RJ, Belsh JM, Lou JS, Levine T, Saperstein D, Miller RG, Scelsa SN; Combination Drug Selection Trial Study Group.

Amyotroph Lateral Scler. 2008 Aug;9(4):212-22. doi: 10.1080/17482960802195632.

16.

Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Igaz LM, Kwong LK, Xu Y, Truax AC, Uryu K, Neumann M, Clark CM, Elman LB, Miller BL, Grossman M, McCluskey LF, Trojanowski JQ, Lee VM.

Am J Pathol. 2008 Jul;173(1):182-94. doi: 10.2353/ajpath.2008.080003. Epub 2008 Jun 5.

17.

High-dimensional spatial normalization of diffusion tensor images improves the detection of white matter differences: an example study using amyotrophic lateral sclerosis.

Zhang H, Avants BB, Yushkevich PA, Woo JH, Wang S, McCluskey LF, Elman LB, Melhem ER, Gee JC.

IEEE Trans Med Imaging. 2007 Nov;26(11):1585-97.

PMID:
18041273
18.

Establishment of a cell model of ALS disease: Golgi apparatus disruption occurs independently from apoptosis.

Gomes C, Palma AS, Almeida R, Regalla M, McCluskey LF, Trojanowski JQ, Costa J.

Biotechnol Lett. 2008 Apr;30(4):603-10. Epub 2007 Nov 15.

PMID:
18004513
19.

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny GM, MacArthur RB, Mitsumoto H, Neville HE, Boylan K, Mozaffar T, Belsh JM, Ravits J, Bedlack RS, Graves MC, McCluskey LF, Barohn RJ, Tandan R; Western ALS Study Group.

Lancet Neurol. 2007 Dec;6(12):1045-53. Epub 2007 Nov 5.

PMID:
17980667
20.

TDP-43 pathologic lesions and clinical phenotype in frontotemporal lobar degeneration with ubiquitin-positive inclusions.

Grossman M, Wood EM, Moore P, Neumann M, Kwong L, Forman MS, Clark CM, McCluskey LF, Miller BL, Lee VM, Trojanowski JQ.

Arch Neurol. 2007 Oct;64(10):1449-54.

PMID:
17923628
21.

Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM.

Science. 2006 Oct 6;314(5796):130-3.

22.

Diffusion tensor imaging in amyotrophic lateral sclerosis: volumetric analysis of the corticospinal tract.

Wang S, Poptani H, Bilello M, Wu X, Woo JH, Elman LB, McCluskey LF, Krejza J, Melhem ER.

AJNR Am J Neuroradiol. 2006 Jun-Jul;27(6):1234-8.

23.

Amyotrophic lateral sclerosis: diffusion-tensor and chemical shift MR imaging at 3.0 T.

Wang S, Poptani H, Woo JH, Desiderio LM, Elman LB, McCluskey LF, Krejza J, Melhem ER.

Radiology. 2006 Jun;239(3):831-8. Epub 2006 Apr 26.

PMID:
16641339
24.

Camptocormia: pathogenesis, classification, and response to therapy.

McCluskey LF.

Neurology. 2006 Apr 25;66(8):1285-6; author reply 1285-6. No abstract available.

PMID:
16636262
25.

Cognitive functioning in sporadic amyotrophic lateral sclerosis: a six month longitudinal study.

Robinson KM, Lacey SC, Grugan P, Glosser G, Grossman M, McCluskey LF.

J Neurol Neurosurg Psychiatry. 2006 May;77(5):668-70.

26.

Venous thrombosis in an ALS population over four years.

Elman LB, Siderowf A, Houseman G, Kelley M, McCluskey LF.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2005 Dec;6(4):246-9.

PMID:
16319029
27.

Nocturnal oximetry: utility in the respiratory management of amyotrophic lateral sclerosis.

Elman LB, Siderowf AD, McCluskey LF.

Am J Phys Med Rehabil. 2003 Nov;82(11):866-70.

PMID:
14566155
28.
29.

Proximal diabetic neuropathy presenting with respiratory weakness.

Brannagan TH, Promisloff RA, McCluskey LF, Mitz KA.

J Neurol Neurosurg Psychiatry. 1999 Oct;67(4):539-41.

30.

Compression and entrapment neuropathies of the lower extremity.

McCluskey LF, Webb LB.

Clin Podiatr Med Surg. 1999 Jan;16(1):97-125, vii. Review.

PMID:
9929774
31.

Absence of electromyographically detectable acute neuromuscular transmission defects after intramuscular interferon-gamma administration.

Constantinescu CS, Fujioka T, Kolson DL, McCluskey LF.

J Neurol. 1998 Jun-Jul;245(6-7):333-4. No abstract available.

PMID:
9669487
32.

Direct muscle stimulation in acute quadriplegic myopathy.

Rich MM, Bird SJ, Raps EC, McCluskey LF, Teener JW.

Muscle Nerve. 1997 Jun;20(6):665-73.

PMID:
9149072
33.
34.

Recurrent migraine and intravenous immune globulin therapy.

Constantinescu CS, Chang AP, McCluskey LF.

N Engl J Med. 1993 Aug 19;329(8):583-4. No abstract available.

PMID:
8336767
35.

Cerebral vasculopathy and infarction in a woman with carcinomatous meningitis.

Gutmann DH, Cantor CR, Piacente GJ, McCluskey LF.

J Neurooncol. 1990 Oct;9(2):183-5. No abstract available.

PMID:
2262804
36.

Unusual presentation of cis-platinum neuropathy.

Mollman JE, Hogan WM, Glover DJ, McCluskey LF.

Neurology. 1988 Mar;38(3):488-90.

PMID:
3347355

Supplemental Content

Loading ...
Support Center